FDA grants priority review for dupilumab in pediatric AD
January 31st 2020The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
Susan Weinkle, M.D., presented JDD outstanding educator award
January 21st 2020South Florida practitioner Dr. Susan Weinkle received the JDD Outstanding Educator & Mentor in Dermatology at the ODAC held Jan.17-20 in Orlando, Fla. The award recognizes continuing contributions to the dermatology industry through education.
New Sol-Gel cream shows positive phase 3 results for acne vulgaris
January 14th 2020Sol-Gel’s new investigational microencapsulated benzoyl peroxide and tretinoin combination cream, Twyneo, for the treatment of acne vulgaris shows promising results from recently released phase 3 data with both clinical trials meeting all primary endpoints.
Psoriasis cream safe, effective suggests EU phase 3 results
December 23rd 2019Results from an EU phase 3 clinical trial of a combination of betamethasone dipropionate and calcipotriene cream showed improved patient convenience, quality of life and efficacy compared to a betamethasone dipropionate and calcipotriene gel for patients with plaque psoriasis.
Tralokinumab meets endpoints for all phase 3 studies
December 16th 2019LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
Fast Track designation granted to lebrikizumab for atopic dermatitis
December 11th 2019The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.
Breakthrough therapy designation granted to nemolizumab for pruritus
December 9th 2019The United States Food and Drug Administration has granted Galderma’s nemolizumab a Breakthrough Therapy Designation following phase 2 results which suggests the drug is a considerable alleviant for pruritus associated with prurigo nodularis.